Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database
View/ Open
Author
Junnila, Mika
Laaksonen, Inari
Eskelinen, Antti
Pulkkinen, Pekka
Ivar Havelin, Leif
Furnes, Ove
Marie Fenstad, Anne
Pedersen, Alma B
Overgaard, Søren
Kärrholm, Johan
Garellick, Göran
Mäkelä, Keijo T
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1080/17453674.2016.1222804Metadata
Show full item recordCitation
Junnila, M., I. Laaksonen, A. Eskelinen, P. Pulkkinen, L. Ivar Havelin, O. Furnes, A. Marie Fenstad, et al. 2016. “Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database.” Acta Orthopaedica 87 (6): 546-553. doi:10.1080/17453674.2016.1222804. http://dx.doi.org/10.1080/17453674.2016.1222804.Abstract
Background and purpose According to previous Nordic Arthroplasty Register Association (NARA) data, the 10-year implant survival of cemented total hip arthroplasties (THAs) is 94% in patients aged 65–74 and 96% in patients aged 75 or more. Here we report a brand-level comparison of cemented THA based on the NARA database, which has not been done previously. Patients and methods We determined the rate of implant survival of the 9 most common cemented THAs in the NARA database. We used Kaplan-Meier analysis with 95% CI to study implant survival at 10 and 15 years, and Cox multiple regression to assess survival and hazard ratios (HRs), with revision for any reason as endpoint and with adjustment for age, sex, diagnosis, and femoral head material. Results: Spectron EF THA (89.9% (CI: 89.3–90.5)) and Elite THA (89.8% (CI: 89.0–90.6)) had the lowest 10-year survivorship. Lubinus (95.7% survival, CI: 95.5–95.9), MS 30 (96.6%, CI: 95.8–97.4), and C-stem THA (95.8%, CI: 94.8–96.8) had a 10-year survivorship of at least 95%. Lubinus (revision risk (RR) = 0.77, CI: 0.73–0.81), Müller (RR =0.83, CI: 0.70–0.99), MS-30 (RR =0.73, CI: 0.63–0.86), C-stem (RR =0.70, CI: 0.55–0.90), and Exeter Duration THA (RR =0.84, CI: 0.77–0.90) had a lower risk of revision than Charnley THA, the reference implant. Interpretation The Spectron EF THA and the Elite THA had a lower implant survival than the Charnley, Exeter, and Lubinus THAs. Implant survival of the Müller, MS 30, CPT, and C-stem THAs was above the acceptable limit for 10-year survival.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119435/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29739059
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)